Anticoagulant treatment for isolated distal deep vein thrombosis: a systematic review and meta-analysis.

To assess the efficacy and safety of anticoagulation in patients with IDDVT we performed a systematic reviewand meta-analysisof randomized and cohort studies on anticoagulation for IDDVT.

为了评估抗凝治疗在IDDVT患者中的疗效和安全性，我们对关于IDDVT抗凝治疗的随机和队列研究进行了系统评价和荟萃分析。

Efficacy outcomes included recurrent deep vein thrombosis (DVT), pulmonary embolism (PE), proximal progression of IDDVT, post-thrombotic syndrome (PTS).

疗效结果包括复发性深静脉血栓形成（DVT）、肺栓塞（PE）、近端进展性IDDVT和血栓后综合征（PTS）

Safety outcomes included major bleeding and clinically relevant non-major bleeding (CRNMB).

安全性结果包括主要出血和临床相关的非主要出血（CRNMB）

Pooled incidenceand risk ratios (RR) with 95% confidence intervals (CI) were calculated.

计算了汇总的发生率和风险比（RR），并附有95%置信区间（CI）。

Treatment duration was defined as short (<6 weeks), long (6-12 weeks), or extended (>12 weeks).

治疗持续时间被定义为短期（<6周）、长期（6-12周）或延长（>12周）。

Fifty-three studies (14,580 patients) were included.

共纳入了53项研究（14,580名患者）。

The incidenceof recurrent DVT and proximal progression was 16% and 11% in untreated patients, 7% and 7% in short, 6% and 3% in long, and 4% and 2% in extended anticoagulation, respectively.

未治疗患者的复发性深静脉血栓形成（DVT）和近端进展的发生率分别为16%和11%，短期抗凝治疗患者为7%和7%，长期抗凝治疗患者为6%和3%，而延长抗凝治疗患者为4%和2%。

The incidenceof PE (2%) and major bleeding (2%) was low, with similar risk across groups of treatment duration.

PE（肺栓塞）的发生率为2%，主要出血的发生率也为2%，各治疗持续时间组的风险相似。

The incidenceof PTS was 30% in untreated patients, 11% in short, and 0% in long anticoagulation.

未经治疗的患者的PTS（血栓后综合征）发生率为30%，短期抗凝治疗的患者为11%，长期抗凝治疗的患者为0%。

The incidenceof CRNMB was respectively 2%, 1%, 4%, and 8%.

CRNMB的发生率分别为2%，1%，4%和8%。

Patients receiving short courses of anticoagulation had higher risk of recurrent VTE (RR=2.72; 95% CI: 1.19-6.23) and proximal progression (RR=3.86; 95% CI: 1.77-8.43) than patients receiving long anticoagulation, with similar bleeding risk in patients with IDDVT, anticoagulation seemed associated with lower risk of recurrent VTE and proximal progression, and similar bleeding risk compared to no anticoagulant treatment.

接受短期抗凝治疗的患者比接受长期抗凝治疗的患者复发性VTE的风险更高（RR=2.72；95% 置信区间：1.19-6.23）和近端进展（RR=3.86；95% 置信区间：1.77-8.43），而对于IDDVT患者，抗凝治疗似乎与较低的复发性VTE和近端进展风险相关，与未接受抗凝治疗的患者相比，出血风险相似。

Long-term treatment duration appeared to be more effective.

长期治疗似乎更有效。